Obviously the company feels that recent studies will indicate the need to go into full blown trials and on an expedited basis, and that requires cash, and lots of it. Better safe than sorry, but let's hope this is the end to the give away secondaries until the price is at least over $5.
The company already said that the recovery exhibited by Jordan after the scaffold was implanted is seen in about 2% of those who had his type of spinal cord injury....By simple logic....and I mean simple...there was approximately then a 98% chance that the positive results obtained to date were likely either because of the scaffold, or devine intervention....Take your pick.
Why anyone in their right mind would go short on one of the hottest stocks in one of the hottest sectors
with one of the most positive charts out there, is beyond me. I guess the operative word is "in their right mind".
2x's gross sales for a medical device company is a very conservative figure, but le't go with that for now.
My target is much the same frankly, as I posted here yesterday. A 1 billion dollar company. Agree
basically with your analysis... Good job.
Mike....You're talking out of both sides of your mouth. You can't post that the projected market size of ("4,000" spinal cord patients....wrong by the way), won't support a much higher market cap, then say at the same time you're looking for 700% return on your investment, or a market cap for the company well over a billion dollars?? When I mentioned I could easily see a market cap for this company of over a billion if the device is proven out , you dismissed that notion off hand...
So tell us "Mike"... What do YOU feel the market cap could be if the device obtains FDA approval.
Stick that lil neck out a bit...We're all waiting...
Mike...Have you not considered you can do both....make money AND help your fellow man at the same time?
First you spout off how bad of an investment longer term NVIV is because the potential target treatment group is too small to justify a large price tag for the company, and now you're into "making money" with this company? As my daddy used to tell me..."Son...sh_t or get off the pot"... Make up you mind man.
Mike...Today this is a 150 million dollar company. Chump change in this day and age if you have anything going for you. There is not a medical device company out there that would not pay over a billion dollars for a company with the state of the art device to treat spinal cord injuries. SRPT is a 500 million dollar biotech with a yet to be approved drug to treat about 150 children worldwide each year for an incurable disease. When it comes to conditions and diseases that are the face of a loved one there is not enough money in the world
to not justify the treatment.
Agree....but the great thing about stocks is they don't go from $1.50 to $50 in a straight upward move one day when FDA approval comes in the mail. If things work out,and no safety issues, (and I agree that is a big "if"),
this stock should gradually move up heading into 2017 (which is only 2 years away). I mean if the stock is $4 by 2017 you've had a return of 50% per annum. Not too shabby if you think about it.
Look...It one is truly interested in getting into the detailed specifics of this company I would suggest you read
Jason Napodano's article of last week on his BioNap site (Twitter) that discusses NVIV. Jason is a CFA and biotech analyst with Zack's. Well worth the read IMHO.
An HDE is obviously just the first step in the process of obtaining final FDA approval. The more times they use the device successfully the shorter the time to final FDA approval will come. I've been involved in a company with a spinal device for scoliosis that got approval after18 successful implants with no safety
issues. The procedures were done under an HDE for children under the ages of 13.
Not sure where you're getting your figures "mike" but go to the World Health Organization website under spinal cord injuries and read the first sentence where it states there are between 250,000 to 500,000 spinal cord injuries per year worldwide. Not obviously all result in either full or partial permanent paralysis. However,a simple device like NVIV has invented could be used extensively in almost all cases if just to lesson compression on the spine and effected vertabraes, and increase blood flow to the injured areas, thus resulting in a speedier recovery in general.
And if the device works in the spine, a like device could probably be effective in other areas of the human skeleton and have further applications. This is not a one trick pony.
We all need to understand that the current "study" is being brought under an IDE (Investigational Device Exemption) and if it proves out to be both effective, and safe, the company then intends to proceed with a pivotal trial under a HDE (Humanitarian Device Exemption), the successful completion of which should garner full FDA approval for use.
I respectfully disagree with your conclusions. Caution is of course warranted in all stock investing, especially in a new technology brought forth by what is essentially a penny stock company. However, all successful companies start small, and with unproven technology. This is a medical device company, not a drug company.
Big difference here. You don't have ten years of trials and three major trials to obtain approval. Much faster process. Been in three that started as private deals, and all had FDA approved devices within three years.
If this works it will be huge. Not kinda huge. Huge. You aren't seeing the future potential for this product.
If it works half as well for others as it apparently has for Jordan, it will be the go to implant for all major spinal cord trauma. And that will be worldwide...not just here in the U.S. Add to that the potential to implant stem cells within the device to actually activate and grow cells and tissue to help even repair damage to the spinal cord, and you tell me what a company that could produce this is worth....
Yes...we're at the very early stages here, but your caution, although duly noted, to me, is simply repeating the obvious.